Indaptus Therapeutics, Inc. (INDP) Stock Analysis

Indaptus Therapeutics developed Decoy20, a patented immunotherapy built from attenuated, non-pathogenic Gram-negative bacteria designed to activate both innate and adaptive immune responses against tumors without a targeted antigen, testing it in a Phase 1 trial that began in 2023 and, since May 2025, in combination with BeOne Medicines' anti-PD-1 antibody tislelizumab. As of this filing, Indaptus has discontinued enrollment in that combination study, has no plans to start a new clinical trial, and is instead pursuing a "Post-Investment Transaction" merger or acquisition of an operating target company following a $6.0 million December 2025 preferred stock investment.

Indaptus has never generated product revenue and has financed operations entirely through equity and debt issuances, including a 1-for-28 reverse stock split in June 2025, a $5.7 million convertible note financing that converted into stock in July 2025, a Standby Equity Purchase Agreement with Yorkville terminated in March 2026, and the December 2025 sale of 300,000 shares of Series AA and 700,000 shares of Series AAA Preferred Stock to David Lazar for $6.0 million, convertible into roughly 111.0 million shares of common stock, or approximately 96.4% of shares outstanding on a fully diluted basis. In February 2026, Lazar-affiliated directors were elected to the Board, existing warrants were repriced to $1.75 per share, and stockholders approved raising authorized common stock to 1.0 billion shares. Decoy20 itself showed preclinical synergy with four drug classes - NSAIDs, checkpoint inhibitors, targeted antibodies, and low-dose chemotherapy - and demonstrated activity against hepatitis B and HIV in animal models, but no Indaptus product candidate has completed a trial designed to show substantial evidence of efficacy.